The Pharmexcil in association with Consulate General of India in Frankfurt, Germany and Chamber of Commerce (IHK) Frankfurt is organizing a one-day online discussion programme on the topic of ‘Challenges and opportunities‘ for the Indian and German pharmaceutical firms in the post C-19 virus times’.
According to Udaya Bhaskar, director general of Pharmexcil, the main objective of the webinar is to discuss on the current prevailing problems and issues faced by the Indian and German pharmaceutical industries and what are the various opportunities available during the post C-19 regime.
“As we all know, the C-19 pandemic has put a big challenge in front of not only the healthcare community but also the entire pharmaceutical industries and research institutions across the globe. Not just the challenges, but the post C-19 time has also thrown up various opportunities for the pharma firms.
In view of this, the webinar will help in exchange of experiences on the impact of C-19 on the German and Indian Pharmaceutical companies and how the corporate sector and government machineries plan to tide over these challenges post the C-19 crisis,” informed the Pharmexcil DG.
Interested members who wish to take part in the webinar are advised to register themselves in advance. Dr. Amit Telang, Council General of India, at Frankfurt, Dr. Jurgen, managing director of International Business IHK, and Norbert Noisser, foreign trade ministry for economic affairs of state of Hesse are expected to participate.
Two technical sessions are expected to be held, the first one willbe led by Murtaza Khorakiwala, managing director Wockhardt, and is expected to deliberate on the topic of role of India as a global vaccine manufacturer. Dr. Werner Schneider, senior director, business development from Harmosan Pharma is expected to deliberate on the topic of challenges for pharma industries during and post C-19 scenario during the second technical session.